357 related articles for article (PubMed ID: 31227713)
1. IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization.
Eissmann MF; Dijkstra C; Jarnicki A; Phesse T; Brunnberg J; Poh AR; Etemadi N; Tsantikos E; Thiem S; Huntington ND; Hibbs ML; Boussioutas A; Grimbaldeston MA; Buchert M; O'Donoghue RJJ; Masson F; Ernst M
Nat Commun; 2019 Jun; 10(1):2735. PubMed ID: 31227713
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol inhibits IL-33-mediated mast cell activation by targeting the MK2/3-PI3K/Akt axis.
Nakajima S; Ishimaru K; Kobayashi A; Yu G; Nakamura Y; Oh-Oka K; Suzuki-Inoue K; Kono K; Nakao A
Sci Rep; 2019 Dec; 9(1):18423. PubMed ID: 31804564
[TBL] [Abstract][Full Text] [Related]
3. Mast cells are essential intermediaries in regulating IL-33/ST2 signaling for an immune network favorable to mucosal healing in experimentally inflamed colons.
He Z; Song J; Hua J; Yang M; Ma Y; Yu T; Feng J; Liu B; Wang X; Li Y; Li J
Cell Death Dis; 2018 Dec; 9(12):1173. PubMed ID: 30518915
[TBL] [Abstract][Full Text] [Related]
4. IL-33/ST2 signalling and crosstalk with FcεRI and TLR4 is targeted by the parasitic worm product, ES-62.
Ball DH; Al-Riyami L; Harnett W; Harnett MM
Sci Rep; 2018 Mar; 8(1):4497. PubMed ID: 29540770
[TBL] [Abstract][Full Text] [Related]
5. Clock-dependent temporal regulation of IL-33/ST2-mediated mast cell response.
Kawauchi T; Ishimaru K; Nakamura Y; Nakano N; Hara M; Ogawa H; Okumura K; Shibata S; Nakao A
Allergol Int; 2017 Jul; 66(3):472-478. PubMed ID: 28259547
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-33 and ST2 Signaling in Tumor Microenvironment.
Hong J; Kim S; Lin PC
J Interferon Cytokine Res; 2019 Jan; 39(1):61-71. PubMed ID: 30256696
[TBL] [Abstract][Full Text] [Related]
7. ST2 Signaling in the Tumor Microenvironment.
Chang CP; Hu MH; Hsiao YP; Wang YC
Adv Exp Med Biol; 2020; 1240():83-93. PubMed ID: 32060890
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-33 in Malignancies: Friends or Foes?
Shen JX; Liu J; Zhang GJ
Front Immunol; 2018; 9():3051. PubMed ID: 30619376
[TBL] [Abstract][Full Text] [Related]
9. IL-33-Stimulated Murine Mast Cells Polarize Alternatively Activated Macrophages, Which Suppress T Cells That Mediate Experimental Autoimmune Encephalomyelitis.
Finlay CM; Cunningham KT; Doyle B; Mills KHG
J Immunol; 2020 Oct; 205(7):1909-1919. PubMed ID: 32859729
[TBL] [Abstract][Full Text] [Related]
10. ATP/IL-33-triggered hyperactivation of mast cells results in an amplified production of pro-inflammatory cytokines and eicosanoids.
Jordan PM; Andreas N; Groth M; Wegner P; Weber F; Jäger U; Küchler C; Werz O; Serfling E; Kamradt T; Dudeck A; Drube S
Immunology; 2021 Nov; 164(3):541-554. PubMed ID: 34142370
[TBL] [Abstract][Full Text] [Related]
11. Beyond IgE: Alternative Mast Cell Activation Across Different Disease States.
Lyons DO; Pullen NA
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098318
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies targeting ST2L Domain 1 or Domain 3 differentially modulate IL-33-induced cytokine release by human mast cell and basophilic cell lines.
Fursov N; Lu J; Healy C; Wu SJ; Lacy E; Filer A; Li Y; Liu C; Lamb R; Jones B; Reddy R; Petley T; Duffy K
Mol Immunol; 2016 Jul; 75():178-87. PubMed ID: 27294560
[TBL] [Abstract][Full Text] [Related]
13. IL-33 promotes gastric tumour growth in concert with activation and recruitment of inflammatory myeloid cells.
Tran CP; Scurr M; O'Connor L; Buzzelli JN; Ng GZ; Chin SCN; Stamp LA; Minamoto T; Giraud AS; Judd LM; Sutton P; Menheniott TR
Oncotarget; 2022; 13():785-799. PubMed ID: 35677533
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of IL-33-mediated stromal interactions in cancer metastasis.
Andersson P; Yang Y; Hosaka K; Zhang Y; Fischer C; Braun H; Liu S; Yu G; Liu S; Beyaert R; Chang M; Li Q; Cao Y
JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333314
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development.
Qi L; Zhang Q; Miao Y; Kang W; Tian Z; Xu D; Xiao W; Fang F
Int J Cancer; 2020 Mar; 146(5):1421-1434. PubMed ID: 31709531
[TBL] [Abstract][Full Text] [Related]
16. Cancer cell-derived interleukin-33 decoy receptor sST2 enhances orthotopic tumor growth in a murine pancreatic cancer model.
Takenaga K; Akimoto M; Koshikawa N; Nagase H
PLoS One; 2020; 15(4):e0232230. PubMed ID: 32340025
[TBL] [Abstract][Full Text] [Related]
17. Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33.
Bandara G; Beaven MA; Olivera A; Gilfillan AM; Metcalfe DD
Eur J Immunol; 2015 Nov; 45(11):3034-44. PubMed ID: 26256265
[TBL] [Abstract][Full Text] [Related]
18. The interleukin-33 receptor ST2 is important for the development of peripheral airway hyperresponsiveness and inflammation in a house dust mite mouse model of asthma.
Zoltowska AM; Lei Y; Fuchs B; Rask C; Adner M; Nilsson GP
Clin Exp Allergy; 2016 Mar; 46(3):479-90. PubMed ID: 26609909
[TBL] [Abstract][Full Text] [Related]
19. Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway.
Lv Y; Zhao Y; Wang X; Chen N; Mao F; Teng Y; Wang T; Peng L; Zhang J; Cheng P; Liu Y; Kong H; Chen W; Hao C; Han B; Ma Q; Zou Q; Chen J; Zhuang Y
J Immunother Cancer; 2019 Feb; 7(1):54. PubMed ID: 30808413
[TBL] [Abstract][Full Text] [Related]
20. IL-33/ST2 as a potential target for tumor immunotherapy.
Jiang W; Lian J; Yue Y; Zhang Y
Eur J Immunol; 2021 Aug; 51(8):1943-1955. PubMed ID: 34131922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
